AFGAS
REGN icon

Allegiance Financial Group Advisory Services’s Regeneron Pharmaceuticals REGN Stock Holding History

Allegiance Financial Group Advisory Services’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-511
Closed -$395K – 233
2026
Q1 		$395K Buy
511
+120
+31% +$91.9K 0.08% 103
2025
Q4 		$302K Buy
+391
New +$266K 0.06% 126

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Amundi
Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Allegiance Financial Group Advisory Services's REGN Position: Q2 2026 in Review

Allegiance Financial Group Advisory Services sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 511 shares — an estimated $395K sold.

Allegiance Financial Group Advisory Services first reported a position in REGN in Q4 2025 and held it in 2 quarters. The position peaked at $395K in Q1 2026. 864 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Allegiance Financial Group Advisory Services reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Allegiance Financial Group Advisory Services sold 511 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $395K.
  • Allegiance Financial Group Advisory Services first reported a position in Regeneron Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Allegiance Financial Group Advisory Services's Regeneron Pharmaceuticals position peaked at $395K in Q1 2026.
  • 864 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Allegiance Financial Group Advisory Services's 13F filing for Q2 2026, filed 27 Jul 2026.